The recent proliferation in new cancer therapies has significantly improved survival and at the same time introduced brand new challenges for nephrologists. Some of these innovative therapies are directly nephrotoxic and others have introduced unique pathogenic mechanisms and patterns of renal injury. This rapidly evolving landscape of malignancy and cancer treatment related kidney injury poses new challenges for the clinician in the evaluation and management of our patients. This updated ASN Onco-Nephrology curriculum addresses some of these novel clinical entities and provides information on innovations in laboratory and diagnostic techniques and on new management strategies that have recently developed.